Back to Search
Start Over
An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer.
- Source :
-
Internal medicine (Tokyo, Japan) [Intern Med] 2022 Oct 01; Vol. 61 (19), pp. 2867-2871. Date of Electronic Publication: 2022 Mar 05. - Publication Year :
- 2022
-
Abstract
- Nivolumab is an immune-checkpoint inhibitor (ICI) that can induce unique treatment-related toxicities, such as immune-related adverse events (irAEs). Myocarditis is a serious irAE with an incidence between 0.06% and 1.14%. Although the peak onset of irAE is generally within three months from the start of treatment, we experienced an autopsy case of late-onset fulminant myocarditis caused by nivolumab in Epstein Barr virus-associated gastric cancer. Pathological complete remission of the primary lesion was confirmed by the autopsy. We should consider possible complications of cardiac irAEs, especially fulminant myocarditis, even beyond three months after starting ICI therapy.
- Subjects :
- Autopsy
Herpesvirus 4, Human
Humans
Immune Checkpoint Inhibitors
Nivolumab
Antineoplastic Agents, Immunological adverse effects
Epstein-Barr Virus Infections
Myocarditis chemically induced
Myocarditis diagnosis
Myocarditis pathology
Stomach Neoplasms chemically induced
Stomach Neoplasms drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1349-7235
- Volume :
- 61
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Internal medicine (Tokyo, Japan)
- Publication Type :
- Academic Journal
- Accession number :
- 35249925
- Full Text :
- https://doi.org/10.2169/internalmedicine.9161-21